In this video, the speaker discusses a startup company called Seniska, which aims to combat aging by targeting cellular rejuvenation. They use oligonucleotide therapies to restore gene expression in aging cells. The video explores the potential of RNA-based technology and its applications in various medical fields, such as skin aging, idiopathic pulmonary fibrosis, osteoarthritis, and age-related macular degeneration. The company focuses on productization strategies that align with established clinical practices. The speaker highlights the importance of academia's role in driving innovation and commercialization. Seniska recently closed a significant seed funding round and appears to have a promising future in the anti-aging space.
Here are the key facts extracted from the text:
1. The startup company Siniska is working on reversing cellular aging.
2. Siniska is a spin-out company from the University of Exeter.
3. They have discovered a new mechanism to control cellular aging using oligonucleotide therapies.
4. They aim to access and rejuvenate damaged genes within cells.
5. Siniska focuses on applications like skin aging, idiopathic pulmonary fibrosis, osteoarthritis, and age-related macular degeneration.
6. They use various delivery mechanisms like topical, injection, and inhalation.
7. The European paradox highlights the challenge of translating academic discoveries into the marketplace.
8. The company has closed its first seed round of funding, totaling 1.3 million.
Please note that these facts are presented in a numbered list for clarity.